Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Ironwood raises 2026 LINZESS guidance as STARS-2 advances

Aug 6, 2026, 7:16 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Guidance upgrade, meaningful LINZESS growth, and debt reduction likely support multiple expansion; near-term catalysts include STARS-2 progress and leadership changes that may increase investor confidence in execution.

AI summary

What happened, with direct paths to the underlying reporting

Ironwood reported Q2 2026 results with LINZESS U.S. net sales of $282.3M (+14% YoY) and total revenue of $113.0M. The company raised 2026 guidance for LINZESS net sales to $1.15–$1.20B and total revenue to $460–$485M, with Adjusted EBITDA >$310M, while advancing the STARS-2 apraglutide program. Leadership changes (interim CFO, new CMO) accompany a higher-growth trajectory but near-term cash flow dynamics may compress.

IRWD raises 2026 LINZESS U.S. net sales guidance to 1.15–1.20B.
Total 2026 revenue guidance raised to 460–485M; Adjusted EBITDA >310M.
Q2 2026 LINZESS U.S. net sales: 282.3M, up 14% YoY.
STARS-2 APRAGLUTIDE trial actively recruiting; potential best-in-class GLP-2.
Interim CFO appointed; Dr. Jeffrey Silber named CMO; debt reduction ongoing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Ironwood raises 2026 LINZESS guidance as STARS-2 advances

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates